AccueilLONA • NASDAQ
add
Athira Pharma
Dernière clôture
10,02 $
Variation sur la journée
9,51 $ - 11,71 $
Plage sur l'année
4,22 $ - 14,19 $
Capitalisation boursière
106,62 M USD
Volume moyen
79,43 k
Ratio cours/bénéfices
-
Rendement (dividendes)
-
Place boursière principale
NASDAQ
Actualités des marchés
Données financières
Compte de résultat
Chiffre d'affaires
Résultat net
| (USD) | déc. 2025info | Variation Y/Y |
|---|---|---|
Chiffre d'affaires | — | — |
Charges d'exploitation | 78,56 M | 404,72 % |
Résultat net | -82,89 M | -452,48 % |
Marge bénéficiaire nette | — | — |
Bénéfice par action | — | — |
EBITDA | -78,32 M | -411,14 % |
Taux d'imposition effectif | — | — |
Bilan
Total des actifs
Total du passif
| (USD) | déc. 2025info | Variation Y/Y |
|---|---|---|
Trésorerie/Invest. court terme | 88,33 M | 72,27 % |
Total des actifs | 92,15 M | 56,78 % |
Total du passif | 64,36 M | 361,77 % |
Total des capitaux propres | 27,79 M | — |
Actions en circulation | 5,35 M | — |
Ratio cours/valeur comptable | 1,93 | — |
Rentabilité des actifs | -321,50 % | — |
Retour sur capitaux | -686,40 % | — |
Flux de trésorerie
Variation nette en trésorerie
| (USD) | déc. 2025info | Variation Y/Y |
|---|---|---|
Résultat net | -82,89 M | -452,48 % |
Trésorerie (opérations) | — | — |
Trésorerie (invest.) | — | — |
Trésorerie (financement) | — | — |
Variation nette en trésorerie | — | — |
Flux de trésorerie dispo. | — | — |
À propos
Athira Pharma is a late clinical stage American biopharmaceutical company developing small-molecule therapeutics targeting neurodegenerative diseases such as Alzheimer's disease and Parkinson's disease. The company's lead candidate, ATH-1017, is in human studies for Alzheimer's disease as of 2021.
The company was founded in 2011 and is headquartered in Seattle. Funding that supports the company is from both public and private investment groups including the Alzheimer's Drug Discovery Foundation, Dolby Family Ventures, the State of Washington's Life Sciences Discovery Fund, The W Fund, WRF Capital, and other private investors.
Leen Kawas served as the company's first President and CEO, but resigned in October 2021, after an independent special committee found she "altered images in scientific papers she authored." In 2025, the company paid a $4 million settlement in relation to allegations that the CEO falsified research to secure a federal grant. On October 21, 2021, Mark Litton, Ph.D., M.B.A. became chief executive officer. Wikipedia
Date de fondation
2011
Siège social
Site Web
Employés
19
